The ameliorative effect of atorvastatin on serum testosterone and testicular oxidant/antioxidant system of HFD-fed male albino rats [version 1; peer review: 2 approved]

Mohammed Esmail¹, Mohammed Kandeil², Ali Mahmoud El-Zanaty³, Mohammed Abdel-Gabbar¹

¹Biochemistry Department, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt
²Biochemistry Department, Faculty of Veterinary Medicine, Beni-Suef University, P.O. Box 62511, Beni-Suef, Egypt
³Chemistry Department, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt

Abstract

Background: There is a mutual effect between central obesity and low total serum testosterone. Moreover, oxidative stress acts as a bridge between obesity and its complications. Taken together, we aimed to evaluate whether atorvastatin (AS), a cholesterol-lowering drug, has protective potential against high fat diet (HFD)-induced low fertility, which was exemplified in serum testosterone determination. Moreover, we aimed to deduce a putative mechanism of action through evaluation of the testicular oxidant/antioxidant system.

Methods: Adult male albino Wistar rats (Rattus norvegicus albinus) were divided into three groups: 1) normal control group, rats were fed a normal diet for four weeks; 2) HFD group, rats were fed an HFD for four weeks; and 3) AS group, rats were fed an HFD and 5 mg/kg/day atorvastatin for the last two weeks of the experiment. Serum atherogenic index, testosterone, and thyroid stimulating hormone were estimated. Moreover, testicular reduced glutathione and malondialdehyde contents, as well as glutathione-S-transferase, superoxide dismutase, and glutathione reductase activities were also determined. The statistical differences were analyzed using analysis of variance (ANOVA).

Results: AS ameliorated the increased level of serum atherogenic index induced by an HFD, as well as testicular malonaldehyde and reduced glutathione levels. On the other hand, AS increased the depleted level and activity of serum testosterone and testicular glutathione reductase, respectively, induced by HFD.

Conclusion: The ameliorative effect of AS on the deteriorated level of total serum testosterone induced by HFD might partially be due to oxidant/antioxidant disturbance. Further studies should be carried out to evaluate mTOR pathway contribution, which could enable researchers to deduce drugs targeting members of the
oxidant/antioxidant system and/or mTOR pathway to ameliorate putative HFD-induced low fertility.

**Keywords**

HFD, atorvastatin, atherogenic index, testosterone, antioxidants, MDA, testis, male rats
Abbreviations
AX, atherogenic index; HDL-c, cholesterol of high-density lipoprotein; AS, atorvastatin; HFD, high fat diet; CN, normal control group; MDA, malondialdehyde; ELFA, enzyme-linked fluorescent assay; ROS, reactive oxygen species; GSH, reduced form of glutathione; SOD, superoxide dismutase; GST, glutathione-S transferase; TG, triacylglycerol; GR, glutathione reductase; TSH, thyroid stimulating hormone

Introduction
Obesity or overweight is related to an elevated risk of many medical problems such as depression and infertility. In those that are obese or overweight, hyperlipidemia can increase the cholesterol content of platelets, endothelial cells, smooth muscle cells, neutrophils and polymorphonuclear leucocytes and may be a source of reactive oxygen species (ROS). Moreover, increased free fatty acidemia and triglyceridemia, which are consequences of high fat diet (HFD) supplementation, are implicated in obesity complications.

The WHO has reported that approximately 1.9 billion people are overweight and 650 million people are obese worldwide. Moreover, defective sperm quality constitutes 30% of infertile couples, who represent around 16% of the worldwide population. Interestingly, no precise cause can be elucidated for primary or secondary infertility in around 25% of couples. Although literature connecting semen parameters and obesity are contradictory, it is thought that there is a mutual effect between low serum testosterone and central obesity. It has been reported that an increased glycerol level, which is HFD-induced, might lead to a leaky blood-testis barrier, disrupting the homeostasis of the tubular fluid and promoting the apoptosis of germ cells.

It has also been suggested that oxidative stress acts as a bridge between obesity and its complications. Dyslipidemia-generated elevated ROS and/or inflammatory substances are considered to be causes of metabolic disorders such as infertility. High ROS levels may render testicular cells ineffective at maintaining a convenient environment for spermatogenesis. Hence, decreasing dyslipidemia may improve HFD-induced poor fertility and atorvastatin (AS), which is a cholesterol-lowering drug, may be beneficial in this way.

Methods
Ethical statement
All animal handling was in accordance with the instructions and guidelines of the Experimental Animal Ethics Committee, Faculty of Science, Beni-Suef University, Egypt (Approval Number: BSU/FS/2020/18).

Experimental animals
A total of 30 apparently healthy adult male albino Wistar rats that initially weighed approximately 85 g were used in the beginning of this study to overcome any sudden death or diseases to rats. Later, we excluded seven rats because they did not achieve serum atherogenic index (AX) > 0.24, required for inclusion. Two rats died after sub-allocation of HFD-fed rats. Table 1 shows the final number of rats used and their allocation. The animals were purchased from Helwan University, Cairo, Egypt and then housed in the Biochemistry Department, Faculty of Science at Beni-Suef University. The rats were acclimatized for one week to exclude any intercurrent infection. Rats were kept in polypropylene cages with well aerated stainless-steel covers in a controlled environment that was maintained under a 12-hour light/dark cycle, a temperature of 24°C (±3°C) and 50–70% humidity. The rats were supplied with a standard diet and had free access to tap water. All efforts were made to reduce the number and suffering of the rats under investigation. These efforts included: 1) continuous checking of animal house air conditioning and continuous and careful supply of drinking water; 2) refreshing the animal house with ordinary air daily for 30 mins; 3) cleaning the cages and the animal house; 4) using the effective anaesthesia dose; 5) carrying out euthanization of animals far away from the other alive rats; 6) carefully disposing of euthanized animals far away from the other alive rats.

Materials
Normal standard food was purchased from Mecca Factory, Beni-Suef, Egypt. The high fat diet consists of the normal rat chow mixed with 15% palm oil and 1% cholesterol in accordance with Matos et al., with some modifications. Compositions of normal standard and high fat foods are illustrated in Table 2. AS was purchased from Egyptian International Pharmaceutical Industries Co (EIPCO) 10th of Ramadan City, Egypt. All other chemicals were of analytical grade and were obtained from standard commercial suppliers.

Animal grouping and experimental procedure
Rats were divided into three groups as shown in Table 1. Selection of animals was carried out haphazardly without performing any prior randomization method.

1. Normal control group (CN): Rats were fed a normal diet, ad libitum, for four weeks; the whole period of the experiment. Rats were also given the equivalent volume of corn oil, as a vehicle, by oral gavage daily for the last two weeks.

| Group | Frequency | Percent |
|-------|-----------|---------|
| CN    | 7         | 33      |
| HFD   | 9         | 43      |
| AS    | 5         | 24      |
| Total | 21        | 100.0   |

CN, normal control; HFD, high fat diet; AS, atorvastatin.
The reaction mix

| Composition          | Normal chow diet | HFD       |
|---------------------|-----------------|-----------|
| Yellow corn         | 60 %            | 50.5 %    |
| Soybean             | 21 %            | 17.3 %    |
| Fibers              | 11 %            | 9.4 %     |
| Mineral mixture     | 4 %             | 3.6 %     |
| Corn gluten         | 2 %             | 1.4 %     |
| Limestone           | 1.5 %           | 1.3 %     |
| NaCl                | 0.5 %           | 0.5 %     |
| Cholesterol         | 0 %             | 1 %       |
| Palm oil            | 0 %             | 15 %      |

2. HFD group: Rats were fed an HFD, ad libitum, for four weeks of the experiment, in addition to equivalent volume of corn oil by oral gavage daily for the last two weeks.

3. AS group: Rats in this group were fed a high fat diet for four weeks and treated orally with a dose of 5 mg/kg/day atorvastatin suspended in corn oil for the last two weeks of the experiment. The dose was double of that used by Oktem et al.\textsuperscript{14}.

The 30 rats were allocated to six cages; five rats/each cage. On the first day, we selected a cage for commencing treatment randomly, then, every day we selected the starting cage serially. Selection of an animal inside each cage was arbitrary. The oral gavage started at 10 AM until nearly 12 AM. Rats treatments were carried out at animal house in Faculty of Science. The route of AS administration was by oral gavage, which is easy and suitable for rats.

The first author was aware of most stages of the experiments. Most of the authors and technicians contributed to animal euthanasia and collection of specimens. Therefore, blinding was not achieved during allocation or treating stages; however, it was achieved during assessment and data analysis stages.

The dose was adjusted every week based on the changes in body weight (b. w.) to ensure a constant dose per kg b. w. of rats over the entire period of study. After two weeks of the onset of the experiment, rats were fasted overnight (10–12 h) and blood samples were collected from the lateral tail vein for screening of the AX according to the formula: log_{10}(TG/HDL-c). Rats that exhibited AX less than 0.24 were excluded. This criterion was defined before any data was collected. Rats with AX more than 0.24 were allocated to the HFD group and AS-administered group for an extra two weeks. At the end of the experiment, the rats were deprived of food overnight and anaesthetized by inhalation with diethyl ether. Blood samples were collected from the jugular vein and then the rats were killed by sudden cervical decapitation while they were anaesthetized.

**Tissue sampling for biochemical tests**

Immediately after weighing the testes, each testis was homogenized in 5 ml cold buffer (100mM potassium phosphate, PH 7.0, containing 2mM EDTA) per gram of tissue. For the biochemical analysis of antioxidants, including reduced glutathione (GSH) levels were determined according to the method of Beutler et al.\textsuperscript{15}. Moreover, glutathione-S-transferase (GST), superoxide dismutase (SOD), and glutathione reductase (GR) activities were also determined\textsuperscript{16–18}. Besides that, determination of malondialdehyde (MDA) level, as an indicator for lipid peroxidation, was also estimated according to Ohkawa et al.\textsuperscript{19}.

**Determination of testicular GSH content.** The protein content of the testicular sample was precipitated by adding an equal volume of 4 % sulphosalicylic acid. After centrifugation, 0.5 ml of the supernatant was added to 4.5 ml of 0.1 mM Bis-(3-carboxy-4-nitrophenyl)-disulfide reagent in 0.1 M phosphate buffer, pH 8. The color intensity was determined spectrophotometrically at 412 nm.

**Determination of testicular GST activity.** After addition of glutathione (0.5 mM), and sodium phosphate buffer (0.1 M), pH 7.3, to the tissue sample, preincubation was carried out for 5 min at 37°C. Then, 1-chloro-2,4-dinitrobenzene (CDNB, 0.5 mM) was added to the incubation mixture. Thereafter, trichloroacetic acid solution (33%) was added and the mixture was centrifuged. The CDNB conjugate was measured in the supernatant at 340 nm. The quantity of enzyme that enhanced the formation of 1µmol of CDNB conjugate/mg protein/min was considered as one unit of enzyme activity. The molar extinction coefficient was 9.6 mM−1 cm−1.

**Determination of testicular SOD activity.** The reaction mixture contained the sample, tris/EDTA buffer, 12.1%, pH 8, and pyrogallol 10 mM. SOD prevents pyrogallol auto-oxidation by removing superoxide anions. As described, 0.1 buffer was mixed with 1 ml tissue sample, then 0.05 ml pyrogallol was added. The absorbency was read at 0 and 10 mins after the addition of pyrogallol. One unit of enzyme activity is the amount of enzyme that resist a 50% change in extinction per one min. The modification used to determine SOD activity was the use of pyrogallol instead of cytochrome c. ΔA/min was calculated as follows:

\[
\text{Enzyme activity (U/ml) = } \frac{\Delta A/\text{min (sample)}}{\Delta A/\text{min (control)}} \times 50 \%
\]

Then U/ml was converted to U/g tissue.

**Determination of testicular MDA content.** 1 ml of tissue homogenate was mixed with 2 ml of trichloroacetic acid.
(TCA, 7.5%) and then centrifuged. 2 ml of the formed supernatant was mixed with thiobarbituric acid (TBA, 0.7 %) and boiled for 10 mins. The color intensity of the reactants (TBA) was measured at 532 nm. An extinction coefficient of 156000 M−1 cm−1 was used for calculation.

**Biochemical assays**

Serum triglyceride levels were determined according to the method of Tietz.

Total serum cholesterol and HDL-cholesterol concentrations were detected according to the procedure of Allain et al.

Serum AX was calculated according to the equation: $AX = \log(TG/HDL-C)$.

AX is a useful measure of response to pharmacological intervention. Total serum testosterone and thyroid stimulating hormone (TSH) were estimated by enzyme-linked fluorescent assay (ELFA).

**Determination of serum triglyceride concentration.** Serum triglyceride concentration was measured using the Randox triglycerides assay (Cat No. TR 213). The kit included reagent 2 which contained 4-chlorophenol (6 mmol/l), magnesium acetate (5 mmol/l), and tris buffer (50 mmol/l). Reagent 3 contained 4-aminoantipyrine (1.0 mmol/l), ATP (1.0 mmol/l), lipases (≥100 U/ml), glycoalkoholase (≥120 U/l), glycerol-3-phosphate oxidase (≥2.5 U/ml), and peroxidase (≥4.0 U/ml). Moreover, the working solution was performed by mixing the contents of reagent 3 with 30 ml of reagent 2. On the other hand, reagent 1 contained triglyceride (200 mg/dl) as a standard. As described, 10 µl of the serum or standard was added to 1 ml of the working reagent and then incubated for 5 min at 37°C. Thereafter, the absorbance of sample (Asample) and standard (Astandard) against reagent blank were measured at 456 nm. Triglycerides level (mg/dl) = (Asample/Astandard) × 200.

**Determination of serum cholesterol concentration.** Serum cholesterol concentration was measured using the Randox Cholesterol assay (Cat No. CH 201). The cholesterol kit included reagent 1 which contained cholesterol (200 mg/dl) as a standard, while reagent 2 contained 3,5 dichloro-2-hydroxybenzene sulfonic acid (4mmol/l), and tris buffer (50mmol/l) detergent (0.2 %). Reagent 3 contained cholesterol esterase (≥160 U/l), cholesterol oxidase (≥ 120 U/l), peroxidase (≥2000 U/l), and 4-aminoantipyrine (0.45 mmol/l). The working solution was prepared by mixing reagent 3 with 30 ml of reagent 2. The procedure for determining of serum total cholesterol level was similar to that of triglyceride determination, except the absorbance measurement was at 500 nm.

**Determination of serum HDL-cholesterol concentration.** Serum HDL-cholesterol concentration was measured using the Randox HDL-cholesterol assay (Cat No. CH 203). Briefly, 50 µl of phosphotungstic acid (13.9 mol/l) was added to 500 µl of sample to precipitate LDL, VLDL and chylomicron fractions in the presence of magnesium ions, allowed to stand for 10 min, centrifuged for 10 min at 4000 rpm. Then, the supernatant was collected to determine the cholesterol content as described before. HDL-cholesterol concentration was calculated as follows:

$$\text{HDL-cholesterol concentration (mg/dl)} = A_{\text{sample}} \times 180.$$
to CN. However, administering AS ameliorated this effect by significantly decreasing serum AX by 18% relative to the HFD-fed group. HFD caused a profound decrease of 62% in total serum testosterone, while AS alleviated this negative effect by increasing the total serum testosterone level by 92% ($p < 0.05$). However, neither HFD nor AS showed a significant effect on serum TSH at $p \geq 0.05$ (Table 3).

Regarding MDA, HFD exerted a tremendous increase in testicular levels of MDA of 113%. AS exhibited an amelioration of this effect, causing a 54% decrease in MDA levels relative to the HFD group ($p < 0.05$). Testicular GSH content was profoundly increased by HFD supplementation by 87%, while AS supplementation caused a 30% decrease in GSH content ($p < 0.05$) (Table 4).

GR activity was decreased by 42% by HFD but increased by 112% by AS ($p < 0.05$). There were moderate increases of 14% and 11% in SOD and GST activities, respectively, after HFD supplementation. However, a decrease of 4% was observed in SOD activity after AS administration ($p < 0.05$), while AS produced an insignificant change in GST activity relative to the HFD group ($p \geq 0.05$) (Table 5).

**Discussion**

Lipid profile amelioration is considered to be an important target in order to foster β-oxidation of fatty acids, otherwise fatty acids would be oriented towards the esterification pathway, leading to accumulation of TAG and LDL cholesterol\textsuperscript{24}. Hence, statins such as AS can help in this trend. They can up-regulate the LDL receptor and reduce cholesterol absorption and biosynthesis, an effect that leads to rapid clearance of LDL particles from circulation\textsuperscript{25}.

Statins were thought to improve sperm parameters regarding dyslipidemia. However, Pons-Rejraji \textit{et al.} rejected this finding, as statins might induce local inflammation or oxidative stress, with persistent effects on prostatic and epididymal secretion\textsuperscript{26}. In agreement with this, some evidence has shown that statins might be detrimental to testosterone production\textsuperscript{27} and might induce impotence\textsuperscript{28}. Other studies indicated that patients undergoing statin therapy to lower serum cholesterol levels have neither androgen deterioration\textsuperscript{29} nor impotence\textsuperscript{30} due to sterol regulatory element binding protein (SREBP)/Srd5a2 system alteration\textsuperscript{31}. The different pharmacokinetic or physicochemical properties of various statins may contribute considerably to total serum testosterone levels.

### Table 3. Changes in serum levels of total testosterone (T. T.; ng/ml), thyroid stimulating hormone (TSH; ng/ml) and atherogenic ratio (AX) as a result of supplementation of AS to HFD-fed rats.

|        | T. T. | % change | TSH | % change | AX | % change |
|--------|-------|----------|-----|----------|----|----------|
| CN    | 2.5±0.2\(^c\) | -        | 1.16±0.37\(^a\) | -    | 0.52±0.005\(^a\) | - |
| HFD   | 0.96±0.04\(^a\) | -62      | 1.08±0.21\(^a\)  | -7   | 0.68±0.03\(^b\)  | 31 |
| AS    | 1.84±0.06\(^b\) | 92       | 1.34±0.35\(^a\)  | 24   | 0.56±0.009\(^a\) | -18 |

Values are expressed as means ± SE. Means that have different superscript letters are significantly different at $P \leq 0.05$. % changes were calculated by comparing HFD means with CN means and AS means with HFD means.

CN, normal control; HFD, high fat diet; AS, atorvastatin.

### Table 4. Changes in testicular levels of malondialdehyde (MDA; nmol/g.tissue) and reduced glutathione (GSH; mg/g.tissue) as a result of supplementation of AS to HFD-fed rats.

|        | MDA   | % change | GSH   | % change |
|--------|-------|----------|-------|----------|
| CN    | 8.4±0.16\(^a\) | -        | 5.96±0.2\(^a\)  | -        |
| HFD   | 17.9±0.56\(^b\) | 113      | 11.14±0.17\(^c\) | 87       |
| AS    | 8.3±0.29\(^a\)  | -54      | 7.84±0.13\(^a\)  | -30      |

Values are expressed as means ± SE. Means that have different superscript letters are significantly different at $P \leq 0.05$. % changes were calculated by comparing HFD means with CN means and AS means with HFD means.

CN, normal control; HFD, high fat diet; AS, atorvastatin.
To share in this debate, we introduced an HFD to rats and treated them with AS. In our experiment, an HFD profoundly decreased serum testosterone, which was counteracted by supplementing with AS, although serum levels were not elevated to that of the normal control. It was previously reported that the decrease of total serum testosterone in obese men is due to increased serum estrogen as a result of increased aromatase activity\(^3\).

The detrimental effects of HFD may be mediated, in our study, via an elevated testicular malondialdehyde level, which is a marker of oxidative stress. However, the ameliorative effect of AS may be partially explicated by lowering serum AX and testicular malondialdehyde levels. Surprisingly, HFD markedly elevated testicular glutathione level and GR activity, which may be a kind of compensatory mechanism. The substantial contribution of the oxidant/antioxidant system in the deterioration effects of HFD on fertility was obvious. Additionally, cholesterol synthesis is not completely inhibited in peripheral tissues in statin-treated patients\(^3\). Therefore, enough cholesterol is available in gonadal and adrenal cells to maintain steroid hormone synthesis; this in line with our data.

Accumulated data suggest mTOR as a promising mechanism for explaining HFD-caused detrimental effects on fertility. In one study, mTOR and p70s6k were weakly expressed in the HFD group, which may be reversed by statin\(^3\).

Our data enables researchers to deduce drugs targeting members of the oxidant/antioxidant system and/or mTOR pathway to ameliorate putative HFD-induced infertility.

### Data availability

**Underlying data**

Harvard Dataverse: Replication Data “The Ameliorative Effect of Atorvastatin on Fertility and Testicular Oxidant/Antioxidant System of HFD-Fed Male Albino Rats”. [https://doi.org/10.7910/DVN/9LEX10\(^3\)].

This project contains the following underlying data:

- Stat (AS).docx (statistics report of data)
- Outcomes (AS).docx (raw GSH, GR, SOD, and GST and MDA levels, as well as serum total testosterone and TSH levels for all 21 rats)

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

### Acknowledgements

The authors thank technical staff members of Biochemistry Department, Faculty of Science, Beni-Suef University for their substantial aid while performing this experiment.

### References

1. Hensley K, Robinson KA, Gabbita SP, et al.: Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000; 28(10): 1456–1462. [PubMed Abstract] [Publisher Full Text]

2. Ghosh A, Gao L, Thakur A, et al.: Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017; 24(1): 50. [PubMed Abstract] [Publisher Full Text] [Free Full Text]
3. Rygiel K: Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies. Curr Cardiol Rev. 2018; 14(1): 67–76. PubMed Abstract | Publisher Full Text | Free Full Text

4. Alahmar AT, Ali Z, Muhsein Z, et al.: The impact of obesity on seminal fluid in men with infertility. Middle East Fertil Soc J. 2018; 23(4): 346–349. Publisher Full Text

5. Drozdzik M, Kaczmarek M, Malinowski D, et al.: TGfβ3 (TGFB3) polymorphism is associated with male infertility. Sci Rep. 2015; 5: 17151. PubMed Abstract | Publisher Full Text | Free Full Text

6. Arcainio D, Favilla V, Tiscione D, et al.: Is there a place for nutritional supplements in the treatment of idiopathic male infertility? Arch Ital Urol Androl. 2014; 86(3): 164–170. PubMed Abstract | Publisher Full Text

7. Brand JS, van der Tweel I, Grobbee DE, et al.: Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2010; 40(1): 189–207. PubMed Abstract | Publisher Full Text

8. Wiebe JP, Kowalik A, Gallardi RL, et al.: Glycerol disrupts tight junction-associated actin microfilaments, occludin, and microtubules in Sertoli cells. J Androl. 2000; 21(5): 625–635. PubMed Abstract

9. Manna P, Jain SK: Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metab Syndr Relat Disord. 2015; 13(10): 423–444. PubMed Abstract | Publisher Full Text | Free Full Text

10. Rani V, Deep G, Singh RK, et al.: Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016; 148: 83–193. PubMed Abstract | Publisher Full Text | Free Full Text

11. Syriou V, Papanikolaou D, Kozrika A, et al.: Cytokines and male infertility. Eur Cytokine Netw. 2018; 29(3): 73–82. PubMed Abstract | Publisher Full Text

12. Rato L, Alves MG, Socorro S, et al.: Metabolic regulation is important for spermatogenesis. Nat Rev Urol. 2012; 9(6): 330–8. PubMed Abstract | Publisher Full Text

13. Matos SL, de Paula H, Pedrosa ML, et al.: Dietary models for inducing hypercholesterolemia in rats. Braz Arch Biol Technol. 2005; 48(2): 203–209. PubMed Abstract | Publisher Full Text

14. Oktém M, Esiner I, Ergülü O, et al.: High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod. 2007; 22(5): 474–480. PubMed Abstract | Publisher Full Text

15. Beutler E, Duron O, Kelly B: Reduced glutathione estimation. J Lab Clin Med. 1963; 62: 51–62.

16. Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974; 249(22): 7130–7139.

17. Nishikimi M, Rao N, Yogi K: Determination of superoxide dismutase in tissue homogenate. Biochem Biophys Res Commun. 1972; 46: 849–854.

18. Goldberg D, Spooner R: Methods of enzymatic analysis. Bergmeyer HW; 1983; 3: 258–265.

19. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2): 351–358. PubMed Abstract | Publisher Full Text

20. Wu AH: Tietz clinical guide to laboratory tests. E-book. Elsevier Health Sciences. 2006. Reference Source

21. Allain CC, Poon LS, Chan CS, et al.: Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20: 573–579. PubMed Abstract | Publisher Full Text

22. Dobíásová M, Frohlich J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (PER). Clin Biochem. 2001; 34(7): 583–588. PubMed Abstract | Publisher Full Text

23. Abdel-Gabbar M, Esmaiil M, Kandeel M, et al.: Replication Data “The Ameliorative Effect of Atorvastatin on Fertility and Testicular Oxidant/Antioxidant System of HFD-Fed Male Albino Rats”. Harvard Dataverse. VS. 2020. http://www.doi.org/10.7910/DVN/RLEX1O

24. Brault M, Ray J, Gomez YH, et al.: Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014; 63(6): 735–745. PubMed Abstract | Publisher Full Text

25. Al-Naazep G, Ismail M, Allaudin Z: Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by thymoquinone-rich fraction and thymoquinone in HepG2 cells. J Nutrigenet Nutrigenomics. 2009; 2(4–5): 163–172. PubMed Abstract | Publisher Full Text

26. Pons-Rejaří H, Brugnon F, Sion B, et al.: Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial. Reprod Biol Endocrinol. 2012; 10: 65. PubMed Abstract | Publisher Full Text | Free Full Text

27. Schooling CM, Au Yeung SL, Freeman G, et al.: The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013; 11: 57. PubMed Abstract | Publisher Full Text | Free Full Text

28. Solomon H, Sarasanghie YP, Feher MD, et al.: Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract. 2006; 60(2): 141–5. PubMed Abstract | Publisher Full Text

29. Coogan PF, Rosenberg L, Strom BL: Statin use and the risk of 10 cancers. Epidemiology. 2007; 18(2): 213–219. PubMed Abstract | Publisher Full Text

30. Herrmann HC, Levine LA, Macaluso JR, et al.: Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006; 3(2): 303–8. PubMed Abstract | Publisher Full Text

31. Seo YK, Zhu B, Jeon TI, et al.: Regulation of steroid S-alpha reductase type 2 (SrSaR2) by sterol regulatory element binding proteins and statin. Exp Cell Res. 2009; 315(18): 3133–3139. PubMed Abstract | Publisher Full Text | Free Full Text

32. Cohen PG: Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses. 2008; 70(2): 358–360. PubMed Abstract | Publisher Full Text

33. Germerhausen JL, Hunt VM, Bostedor RG, et al.: Tissue selectivity of the cholesterol lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun. 1989; 158(3): 667–675. PubMed Abstract | Publisher Full Text

34. Cui X, Long C, Zhu J, et al.: Protective Effects of Fluvastatin on Reproductive Function in Obese Male Rats Induced by High-Fat Diet through Enhanced Signaling of mTOR. Cell Physiol Biochem. 2017; 41(2): 598–608. PubMed Abstract | Publisher Full Text
Open Peer Review

Current Peer Review Status: ✓ ✓

Version 1

Reviewer Report 10 February 2021

https://doi.org/10.5256/f1000research.28612.r77679

© 2021 Waly M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mostafa Waly
Food Science and Nutrition Department, College of Agricultural and Marine Sciences, Sultan Qaboos University, Muscat, Oman

This is a well written article and the theme of the reported research will add needed knowledge in the field.

I have few minor comments to optimize the quality of the manuscript as follow:

- Please provide the weight gain of the experimental animals throughout the duration of the experiment. I would recommend a figure as an illustration.

- The statistical analysis, One Way ANOVA, should be followed by post analysis; for example Tukey's test. This will provide significant power for the reported results.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Biochemistry and oxidative Stress

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 25 January 2021

https://doi.org/10.5256/f1000research.28612.r75299

© 2021 Mousa A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ahmed A. Mousa
Department of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt

Authors have done a good effort in this work and they concluded that AS has ameliorative effect on the deteriorated level of total serum testosterone induced by HFD might partially be due to oxidant/antioxidant disturbance.

Major comments:
- Would you have a reference for induction of obesity in just for 4 weeks with palm oil and cholesterol?
- What was the final weight of rats at the end of experiment?
- Why did authors not provide any study on assessment of sperm parameters?
- EIPCO Commercial HFD, what is the purpose for it in markets or is it only for research purposes?
- Why did authors not formulate HFD by themselves?
- Please add name and model of spectrophotometer and ELISA plate reader.

Minor comment
- Add the full name of mTOR in abstract section and abbreviations section.

In Methods: delete **All efforts were made to reduce the number and suffering of the rats under investigation. These efforts included: 1) continuous checking of animal house air conditioning and continuous and careful supply of drinking water; 2) refreshing the animal house with ordinary air daily for 30 mins; 3) cleaning the cages and the animal house; 4) using the effective anesthesia
dose; 5) carrying out euthanasia of animals far away from the other alive rats; 6) carefully disposing of euthanized animals far away from the other alive rats**.

**The first author was aware of most stages of the experiments. Most of the authors and technicians contributed to animal euthanasia and collection of specimens. Therefore, blinding was not achieved during allocation nor treating stages; however, it was achieved during assessment and data analysis stages**.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Oxidative stress and andrology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Comments on this article**

**Version 1**

Reader Comment 15 Jan 2021

**kamal Amin**, Imam Abdulrahman Bin Faisal university, KSA, Dammam, Saudi Arabia

I Have been read the manuscript, it provides a important information about HFD and testosterone and oxidant and antioxidant, however some comments are raised need to be revised.

**Major comments:**
*Is 4 weeks of HFD is enough to produce hypercholesterolemia
*Why the author measure TSH, what is the relation to the protocol of the study (reproduction) need to be explain.
*The goal of the study is to induce reproductive disorder by HFD and its treatment with Ator
*

**Materials and Methods**
*Why author choose palm oil instead of beef tallow as source of fat .
*The amount of dietary composition, proteins, fat carbohydrate should be provided

**Results:**
*Table 3 showed non significant role of TSH between group what is the important of its measurement for the study.
*Table 4 GSH as antioxidant biomarkers should be decrease in HFD group, however in the table it increases, need to be revised.
*How HFD decrease the level of TT , since HFD increase the serum cholesterol
*Fertility parameters required to be focus on specially Sperm count etc.

**Discussion:**
-How Ator which is lowering cholesterol medication act as antioxidant, what is the mechanism, is it related to lower cholesterol. Please Provide reference and mechanism.

**Minor comment**
Did the HFD group continue on HF feeding until the end of the experiment (last 2 weeks)

- Use Cr instead **CN for control**
- Reference Pons-Rejrai *et al what is the number

**Competing Interests:** No competing of interest
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com